The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia. This evidence concerns the gene BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive.